Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland.
Division of infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.
Swiss Med Wkly. 2021 Jul 19;151:w20572. doi: 10.4414/smw.2021.20572.
The aim of this study was to analyse the demographics, risk factors and in-hospital mortality rates of patients admitted with coronavirus disease 2019 (COVID-19) to a tertiary care hospital in Switzerland.
In this single-centre retrospective cohort study at the University Hospital Basel, we included all patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection hospitalised from 27 February 2020 to 10 May 2021. Patients’ characteristics were extracted from the electronic medical record system. The primary outcome of this study was temporal trends of COVID-19-related in-hospital mortality. Secondary outcomes were COVID-19-related mortality in patients hospitalised on the intensive care unit (ICU), admission to ICU, renal replacement therapy and length of hospital stay, as well as a descriptive analysis of risk factors for in-hospital mortality.
During the study period we included 943 hospitalisations of 930 patients. The median age was 65 years (interquartile range [IQR] 53–76) and 63% were men. The numbers of elderly patients, patients with multiple comorbidities and need for renal replacement therapy decreased from the first and second to the third wave. The median length of stay and need for ICU admission were similar in all waves. Throughout the study period 88 patients (9.3%) died during the hospital stay. Crude in-hospital mortality was similar over the course of the first two waves (9.5% and 10.2%, respectively), whereas it decreased in the third wave (5.4%). Overall mortality in patients without comorbidities was low at 1.6%, but it increased in patients with any comorbidity to 12.6%. Predictors of all-cause mortality over the whole period were age (adjusted odds ratio [aOR] per 10-year increase 1.81, 95% confidence interval [CI] 1.45–2.26; p <0.001), male sex (aOR 1.68, 95% CI 1.00–2.82; p = 0.048), immunocompromising condition (aOR 2.09, 95% CI 1.01–4.33; p = 0.048) and chronic kidney disease (aOR 2.25, 95% CI 1.35–3.76; p = 0.002).
In our study in-hospital mortality was 9.5%, 10.2% and 5.4% in the first, second and third waves, respectively. Age, immunocompromising condition, male sex and chronic kidney disease were factors associated with in-hospital mortality. Importantly, patients without any comorbidity had a very low in-hospital mortality regardless of age.
本研究旨在分析在瑞士一家三级保健医院因 2019 年冠状病毒病(COVID-19)入院的患者的人口统计学、危险因素和院内死亡率。
在巴塞尔大学医院的这项单中心回顾性队列研究中,我们纳入了 2020 年 2 月 27 日至 2021 年 5 月 10 日期间因确诊严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染而住院的所有患者。从电子病历系统中提取患者特征。本研究的主要结局是 COVID-19 相关院内死亡率的时间趋势。次要结局是 COVID-19 相关 ICU 死亡率、ICU 入院、肾脏替代治疗和住院时间以及院内死亡率相关危险因素的描述性分析。
在研究期间,我们纳入了 930 名患者的 943 例住院治疗。中位年龄为 65 岁(四分位距 53-76),63%为男性。老年患者、合并多种疾病患者和需要肾脏替代治疗患者的数量从第一波和第二波减少到第三波。各波的中位住院时间和 ICU 入院需求相似。整个研究期间,88 名(9.3%)患者在住院期间死亡。前两波的院内死亡率相当(分别为 9.5%和 10.2%),而第三波则降低(5.4%)。无合并症患者的总体死亡率较低,为 1.6%,但有任何合并症患者的死亡率增加至 12.6%。整个研究期间全因死亡率的预测因素包括年龄(每增加 10 岁的调整优势比[OR]为 1.81,95%置信区间[CI]为 1.45-2.26;p <0.001)、男性(OR 1.68,95%CI 1.00-2.82;p = 0.048)、免疫抑制状况(OR 2.09,95%CI 1.01-4.33;p = 0.048)和慢性肾脏病(OR 2.25,95%CI 1.35-3.76;p = 0.002)。
在我们的研究中,第一波、第二波和第三波的院内死亡率分别为 9.5%、10.2%和 5.4%。年龄、免疫抑制状况、男性和慢性肾脏病是与院内死亡率相关的因素。重要的是,无论年龄大小,无任何合并症的患者院内死亡率非常低。